Changes in Beneficial Ownership · 4
BioStem Technologies, Inc.
BSEMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-07
- Issuer
- BioStem Technologies, Inc.
- Issuer CIK
- 0001658678
- Trading symbol
- BSEM
Reporting owner 1
- Name
- Matuszewski Jason
- Reporting owner CIK
- 0001634730
- Relationship
- Director · Officer · 10% owner
- Officer title
- Chief Executive Officer
- Address
- C/O BIOSTEM TECHNOLOGIES, INC., 2836 CENTER PORT CIRCLE, POMPANO BEACH, FL, 33064
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-07 | M · Form 4 | 250,000 | A | 2.00 | 1,553,551[F1] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Options (Right to Buy) | 2.00 | 2026-10-07 | M · Form 4 | 250,000 | D | 0.00 | [F5] | 2032-10-24 | Common Stock | 250,000 | 2,000,000 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Amount owned | Ownership |
|---|---|---|---|---|---|---|---|
| Series A-1 Convertible Preferred Shares | [F2] | 2016-05-23 | [F3] | Common Stock | 100 | 100[F4] | D |
| Options (Right to Buy) | 10.05 | [F6] | 2035-03-17 | Common Stock | 198,807 | 198,807 | D |
| Options (Right to Buy) | 10.05 | [F7] | 2035-10-13 | Common Stock | 40,427 | 40,427 | D |
| Options (Right to Buy) | 5.50 | [F8] | 2036-02-11 | Common Stock | 440,529 | 440,529 | D |
| Restricted Stock Units | [F9] | [F10] | [F10] | Common Stock | 33,874 | 33,874 | D |
| Restricted Stock Units | [F9] | [F11] | [F11] | Common Stock | 99,901[F1] | 99,901[F1] | D |
| Restricted Stock Units | [F9] | [F12] | [F12] | Common Stock | 363,636 | 363,636 | D |
Table key
- D
- Direct
Footnotes
- F1
- The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error.↩ 1↩ 2↩ 3
- F2
- The Series A-1 Convertible Preferred Shares is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.↩ 1
- F3
- The Series A-1 Convertible Preferred Shares have no expiration date.↩ 1
- F4
- Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.↩ 1
- F5
- These options are fully vested and exercisable.↩ 1
- F6
- These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.↩ 1
- F7
- These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.↩ 1
- F8
- These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.↩ 1
- F9
- Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.↩ 1↩ 2↩ 3
- F10
- These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).↩ 1↩ 2
Signature 1
- Signed
- /s/ Katherine Gorrell, Attorney-in-Fact
- Date
- 2026-10-09
Company context
BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.